Display options
Cite
Belleudi V, Marchetti F, Finocchietti M, et al. Palivizumab reimbursement criteria and neonatal RSV hospitalisation: a regional retrospective review. BMJ Paediatr Open. 2021;5(1):e000985doi: 10.1136/bmjpo-2020-000985.
Belleudi, V., Marchetti, F., Finocchietti, M., Davoli, M., & Addis, A. (2021). Palivizumab reimbursement criteria and neonatal RSV hospitalisation: a regional retrospective review. BMJ paediatrics open, 5(1), e000985. https://doi.org/10.1136/bmjpo-2020-000985
Belleudi, Valeria, et al. "Palivizumab reimbursement criteria and neonatal RSV hospitalisation: a regional retrospective review." BMJ paediatrics open vol. 5,1 (2021): e000985. doi: https://doi.org/10.1136/bmjpo-2020-000985
Belleudi V, Marchetti F, Finocchietti M, Davoli M, Addis A. Palivizumab reimbursement criteria and neonatal RSV hospitalisation: a regional retrospective review. BMJ Paediatr Open. 2021 Mar 01;5(1):e000985. doi: 10.1136/bmjpo-2020-000985. eCollection 2021. PMID: 33748434; PMCID: PMC7925248.
Copy Download .nbib Format: NLM
Share it on

BMJ Paediatr Open. 2021 Mar 01;5(1):e000985. doi: 10.1136/bmjpo-2020-000985. eCollection 2021.

Palivizumab reimbursement criteria and neonatal RSV hospitalisation: a regional retrospective review.

BMJ paediatrics open

Valeria Belleudi, Federico Marchetti, Marco Finocchietti, Marina Davoli, Antonio Addis

Affiliations

  1. Department of Epidemiology, Regional Health Service, Azienda Sanitaria Locale Roma 1, Roma, Italy.
  2. Pediatrics, AUSL Ravenna, Ravenna, Italy.

PMID: 33748434 PMCID: PMC7925248 DOI: 10.1136/bmjpo-2020-000985

Abstract

In Italy, reimbursement restrictions regarding palivizumab prophylaxis approved in 2016 have been revoked in 2017, restoring use in infants with Gestational Age (GA) >29 weeks. Respiratory Syncytial Virus (RSV) hospitalisations and prevalence of palivizumab use in infants aged <6 months during five seasons (2014-2019), were considered according to different GA. Although RSV hospitalisations rate showed no significant changes, during different seasons in all GA, lower prevalence of palivizumab use in 2016 (0.8% vs 0.3%), returned to a higher level following the revoke of restrictions. Changes in reimbursement criteria were not associated with neonatal RSV hospitalisations rate but with a significant impact on palivizumab use.

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Keywords: neonatology; pharmacology; therapeutics

Conflict of interest statement

Competing interests: None declared.

References

  1. Pediatrics. 2014 Aug;134(2):e620-38 - PubMed
  2. Pediatr Pulmonol. 2016 Oct;51(10):1088-1096 - PubMed
  3. Arch Dis Child. 2018 Dec;103(12):1163-1167 - PubMed
  4. J Pediatr. 2019 Jun;209:125-129 - PubMed
  5. Pediatrics. 2016 Aug;138(2): - PubMed

Publication Types